Core Viewpoint - The stock of Meihao Medical (301363) has shown a decline of 1.05% on October 28, 2025, closing at 23.46 yuan, with mixed capital flow trends indicating a slight net inflow from main funds and a net outflow from retail investors [1][2]. Financial Performance - For the third quarter of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43%, indicating a relatively strong profitability compared to the industry average [3]. Market Position - Meihao Medical's total market capitalization is 13.346 billion yuan, ranking 25th in the medical device industry, while its net assets are 3.702 billion yuan, ranking 40th [3]. - The company has a price-to-earnings ratio (P/E) of 48.07, which is lower than the industry average of 54.16, suggesting a potentially favorable valuation [3]. Capital Flow Analysis - On October 28, 2025, the main funds had a net inflow of 2.2667 million yuan, accounting for 2.06% of the total transaction amount, while retail investors experienced a net inflow of 109,300 yuan [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant net outflows from retail investors on several days, indicating varying investor sentiment [2]. Institutional Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4].
股票行情快报：美好医疗（301363）10月28日主力资金净买入226.67万元